公开(公告)号：US20240342260A1

公开(公告)日：2024-10-17

申请号：US18638402

申请日：2024-04-17

申请人： ZAG Bio, Inc.

发明人： Alan Crane ,  John Kulman ,  Joanne L. Viney

IPC分类号： A61K39/00 ,  A61P37/06 ,  C07K14/47 ,  C07K14/705 ,  C07K16/18 ,  C07K16/26 ,  C07K16/28 ,  C07K16/30

CPC分类号： A61K39/0008 ,  A61P37/06 ,  C07K14/4713 ,  C07K14/70503 ,  C07K16/18 ,  C07K16/26 ,  C07K16/28 ,  C07K16/2803 ,  C07K16/283 ,  C07K16/2833 ,  C07K16/2851 ,  C07K16/2896 ,  C07K16/30 ,  A61K2039/505 ,  A61K2039/577 ,  A61K2039/6056 ,  C07K2317/52 ,  C07K2317/71 ,  C07K2319/33 ,  C07K2319/40

摘要： Embodiments provided herein, provide for polypeptides, pharmaceutical compositions, and methods that can be used to target at least two types of cells to modulate the activity of the same to treat disorders, such as autoimmune disorders.

公开(公告)号：US12077581B2

公开(公告)日：2024-09-03

申请号：US17553280

申请日：2021-12-16

申请人： H. LUNDBECK A/S

发明人： Maria-Cristina Loomis ,  Leon F. Garcia-Martinez ,  Benjamin H. Dutzar ,  Daniel S. Allison ,  Katherine Lee Hendrix ,  Ethan W. Ojala ,  Pei Fan ,  Jeffrey T. L. Smith ,  John A. Latham ,  Charlie Karasek ,  Jenny Mulligan ,  Michelle Scalley-Kim ,  Erica Stewart ,  Vanessa Lisbeth Rubin ,  Jens J. Billgren

IPC分类号： C07K16/26 ,  A61K39/395 ,  A61P25/06 ,  A61K39/00 ,  A61K45/06 ,  A61K49/00 ,  C07K14/575 ,  C07K16/42 ,  G01N33/50 ,  G01N33/74

CPC分类号： C07K16/26 ,  A61K39/3955 ,  A61P25/06 ,  A61K39/39566 ,  A61K2039/505 ,  A61K45/06 ,  A61K49/0004 ,  A61K49/0008 ,  C07K14/57536 ,  C07K14/57563 ,  C07K16/4241 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/40 ,  C07K2317/50 ,  C07K2317/54 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/76 ,  C07K2317/92 ,  G01N33/5088 ,  G01N33/74 ,  G01N2333/5757 ,  Y02A50/30

摘要： The present invention is directed to antagonistic antibodies and antigen binding fragments thereof having binding specificity for PACAP. These antibodies inhibit, block or neutralize at least one biological effect associated with PACAP, e.g., vasodilation. In exemplary embodiments these antibodies and antigen binding fragments thereof may comprise specific VH, VL, and CDR polypeptides described herein. In some embodiments these antibodies and antigen binding fragments thereof bind to and/or compete for binding to specific epitope(s) on human PACAP. The invention is further directed to using these antagonistic anti-PACAP antibodies, and binding fragments thereof, for the diagnosis, assessment, and treatment of diseases and disorders associated with PACAP and conditions where antagonism of PACAP-related activities, such as vasodilation, mast cell degranulation, and/or neuronal activation, are therapeutically beneficial, e.g., headache and migraine indications.

公开(公告)号：US20240261421A1

公开(公告)日：2024-08-08

申请号：US18614508

申请日：2024-03-22

申请人： AMGEN INC.

发明人： KENNETH W. WALKER ,  JERRY RYAN HOLDER ,  DAVID J. LLOYD ,  SHU-CHEN LU ,  MURIELLE M. VENIANT-ELLISON ,  SHANAKA STANISLAUS

IPC分类号： A61K47/65 ,  C07K14/72 ,  C07K16/26

CPC分类号： A61K47/65 ,  C07K14/72 ,  C07K16/26 ,  C07K2317/21 ,  C07K2317/31 ,  C07K2317/565 ,  C07K2317/94 ,  C07K2319/30

摘要： Methods of treating metabolic diseases and disorders using a composition comprising a GLP-1/GIPR antigen binding protein fusion protein are provided. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy. In certain embodiments the composition comprises the C-terminus of a GLP-1 analog fused to the N-terminus of the light chain variable or heavy chain variable region of an antibody or functional fragment thereof that binds GIPR, optionally with a linker in between.

公开(公告)号：US11993648B2

公开(公告)日：2024-05-28

申请号：US16953443

申请日：2020-11-20

申请人： H. LUNDBECK A/S ,  The University of Iowa Research Foundation

发明人： Adisa Kuburas ,  Bianca Mason ,  Levi P. Sowers ,  Andrew F. Russo ,  Maria-Cristina Loomis ,  Leon F. Garcia-Martinez ,  Benjamin H. Dutzar ,  Daniel S. Allison ,  Katherine Lee Hendrix ,  Ethan W. Ojala ,  Pei Fan ,  Jeffrey T. L. Smith ,  John A. Latham ,  Charlie Karasek ,  Jenny Mulligan ,  Michelle Scalley-Kim ,  Erica Stewart ,  Vanessa Lisbeth Rubin ,  Jens J. Billgren

IPC分类号： A61K39/395 ,  A61P25/06 ,  C07K16/26 ,  A61K39/00 ,  A61K45/06 ,  A61K49/00 ,  C07K14/575 ,  C07K16/42 ,  G01N33/50 ,  G01N33/74

CPC分类号： C07K16/26 ,  A61K39/3955 ,  A61P25/06 ,  A61K39/39566 ,  A61K2039/505 ,  A61K45/06 ,  A61K49/0004 ,  A61K49/0008 ,  C07K14/57536 ,  C07K14/57563 ,  C07K16/4241 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/40 ,  C07K2317/50 ,  C07K2317/54 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/76 ,  C07K2317/92 ,  G01N33/5088 ,  G01N33/74 ,  G01N2333/5757 ,  Y02A50/30

摘要： This invention relates to methods of screening for anti-PACAP antibodies, or anti-PACAP receptor antibodies, and antigen binding fragments thereof, for potential use in treating or preventing PACAP-associated photophobia or light aversion, and therapeutic compositions containing and methods of using anti-PACAP antibodies, or anti-PACAP receptor antibodies, and antigen binding fragments thereof.

公开(公告)号：US20240158481A1

公开(公告)日：2024-05-16

申请号：US18328960

申请日：2023-06-05

申请人： Teva Pharmaceuticals International GmbH

发明人： Joerg Zeller ,  Kristian T. Poulsen ,  Yasmina Noubia Abdiche ,  Jaume Pons ,  Sierra Jones Collier ,  Arnon Rosenthal

IPC分类号： C07K16/18 ,  A61K31/4045 ,  A61K39/395 ,  C07K16/26

CPC分类号： C07K16/18 ,  A61K31/4045 ,  A61K39/3955 ,  C07K16/26 ,  A61K2039/505 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/70

摘要： The invention features methods for preventing or treating CGRP associated disorders such as vasomotor symptoms, including headaches (e.g., migraine, cluster headache, and tension headache) and hot flushes, by administering an anti-CGRP antagonist antibody. Antagonist antibody G1 and antibodies derived from G1 directed to CGRP are also described.

公开(公告)号：US11891435B2

公开(公告)日：2024-02-06

申请号：US17558032

申请日：2021-12-21

申请人： AMGEN INC.

发明人： Neeraj Jagdish Agrawal ,  Kevin Graham ,  Agnes Eva Hamburger ,  Christopher Mohr ,  Derek E. Piper ,  Kenneth William Walker ,  Zhulun Wang ,  Cen Xu

IPC分类号： C07K16/00 ,  A61K39/395 ,  A61K39/00 ,  A61K49/00 ,  A61K49/16 ,  C12P21/08 ,  G01N33/53 ,  C07K16/18 ,  C07K16/28 ,  A61P25/06 ,  A61K38/22 ,  A61K47/68 ,  A61K38/17 ,  A61K51/10 ,  C07K14/575 ,  C07K16/26 ,  C07K14/72 ,  C07K14/47 ,  G01N33/74 ,  G01N33/68

CPC分类号： C07K16/18 ,  A61K38/2278 ,  A61P25/06 ,  C07K16/2869 ,  A61K38/1796 ,  A61K38/22 ,  A61K47/6843 ,  A61K47/6849 ,  A61K51/10 ,  A61K2039/505 ,  A61K2039/545 ,  A61K2300/00 ,  C07K14/47 ,  C07K14/575 ,  C07K14/57563 ,  C07K14/72 ,  C07K16/00 ,  C07K16/26 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/51 ,  C07K2317/515 ,  C07K2317/52 ,  C07K2317/522 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/70 ,  C07K2317/72 ,  C07K2317/76 ,  C07K2317/90 ,  C07K2317/92 ,  C12N2501/30 ,  G01N33/6854 ,  G01N33/6896 ,  G01N33/74 ,  G01N2333/575 ,  G01N2333/5757 ,  Y02A50/30

摘要： The present invention relates to neutralizing antibodies of the human pituitary adenylate cyclase activating polypeptide type I receptor (PAC1) and pharmaceutical compositions comprising such antibodies. Methods of treating or preventing headache conditions, such as migraine and cluster headache, using the neutralizing antibodies are also described.

公开(公告)号：US20240034782A1

公开(公告)日：2024-02-01

申请号：US18365991

申请日：2023-08-05

申请人： Board of Regents, The University of Texas System

发明人： Philipp E. Scherer ,  Shangang Zhao

IPC分类号： C07K16/26 ,  A61P3/04 ,  A61P3/10

CPC分类号： C07K16/26 ,  A61P3/04 ,  A61P3/10

摘要： Obesity and/or diabetes are treated by partially inhibiting circulating leptin in a person in need thereof.

公开(公告)号：US20240018264A1

公开(公告)日：2024-01-18

申请号：US18359380

申请日：2023-07-26

申请人： Progastrine et Cancers S.à r.l.

发明人： Alexandre PRIEUR

IPC分类号： C07K16/30 ,  G01N33/574 ,  C07K16/26 ,  A61P35/00

CPC分类号： C07K16/3069 ,  G01N33/57449 ,  C07K16/26 ,  A61P35/00 ,  C07K2317/24 ,  C07K2317/34 ,  C07K2317/73 ,  C07K2317/76 ,  G01N2333/595 ,  A61K2039/505

摘要： The present invention relates to methods for the in vitro diagnosis of ovarian cancer, and to compositions and methods for the prevention or the treatment of ovarian cancer. Disclosed are compositions that include an antibody binding to progastrin and disclosed are methods that include the use of an antibody binding to progastrin.

公开(公告)号：US20230398084A1

公开(公告)日：2023-12-14

申请号：US18239557

申请日：2023-08-29

申请人： Resarcion LLC

发明人： Pedram HAMRAH ,  Reza MOLLAAGHABABA

IPC分类号： A61K9/70 ,  C07K16/26

CPC分类号： A61K9/7038 ,  C07K16/26

摘要： Embodiments of the innovation relate to a dermal patch, comprising a substrate; a set of projections coupled to the substrate and configured to be at least partially insertable into skin, at least a portion of each projection of the set of projections comprising a biodegradable material; and a ghrelin blocker material encapsulated in the plurality of projections. The set of projections are coupled to the substrate via an adhesive that is configured to be dissolved within the skin after the patch is applied to the skin for a predetermined time, thus resulting in separation of the set of projections from the substrate. Once embedded in the skin, the protrusions can degrade and release the anti-ghrelin antibody encapsulated therein. The released anti-ghrelin antibody can find its way into the subject's circulatory system.

公开(公告)号：US11780914B2

公开(公告)日：2023-10-10

申请号：US17031674

申请日：2020-09-24

申请人： AMGEN INC.

发明人： Agnes E. Hamburger ,  Cen Xu ,  Hong Sun ,  Yuan D. Shih ,  Dohan Weeraratne

IPC分类号： A61K39/395 ,  C07K16/26 ,  C12N15/13 ,  A61P25/06 ,  C07K16/42 ,  A61K39/00 ,  A61K9/00

CPC分类号： C07K16/26 ,  A61P25/06 ,  C07K16/4283 ,  A61K9/0019 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/34 ,  C07K2317/565 ,  C07K2317/76

摘要： The present invention relates to monoclonal antibodies that specifically bind to human pituitary adenylate cyclase activating polypeptide (PACAP) and pharmaceutical compositions comprising such antibodies. Methods of treating or preventing headache conditions, such as migraine and cluster headache, using the monoclonal antibodies are also described.